Derek Maetzold News Today

Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript May 4, 2024 Castle Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Castle Biosciences First Quarter 2024 Conference Call. As a remainder, today’s call […]

Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $255-265 million from $235-240...

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that, for the second year in a row, its chief financial officer, Frank Stokes,...

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that Rodney Cotton has been appointed to its board of directors, effective...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Mar 27, 2024--

Company honored for creating an exceptional, people-first culture that empowers employees and fosters trust, transparency and authenticity ...

Operator: Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2023 Conference Call. As a reminder, todays call is being recorded.

Full-Year Revenue Surges by 60% with Significant Advances in Dermatological and Gastroenterological Diagnostics

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that its Chief Operating Officer, Kristen Oelschlager, has been named to The...

Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022 Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash,...